Slovo úvodem

doc. MUDr. Pavel Štourač, Ph.D.

Neurol. praxi 2017; 18(Suppl F): 4  

Cladribine – mechanism of action

prof. MUDr. Eva Kubala Havrdová, CSc.

Neurol. praxi 2017; 18(Suppl F): 5-8 | DOI: 10.36290/neu.2017.122  

Cladribine represents a novel possibility of multiple sclerosis treatment. Mechanism of action is derived from observation of adenosindeaminase deficiency in severe combined immunodeficit. Cladribin exerts incomplete depletion of both activated and restingT- and B- lymphocytes, with repopulation which induces long-term shift in immune system function including change in cytokineproduction. When this effect is compared with alemtuzumab we observe difference in repopulation of B lymphocytes which donot jump above baseline values in patients treated with cladribine. This may explain no occurence of secondary autoimmunities.

Treatment of multiple sclerosis with oral cladribine: results of clinical trials

MUDr. Ivana Kovářová

Neurol. praxi 2017; 18(Suppl F): 9-12 | DOI: 10.36290/neu.2017.123  

Cladribine tablets has been registered recently for treatment of relapsing multiple sclerosis. The article presents results of thepivotal clinical trial CLARITY and its extension – efficacy of cladribine tablets on clinical and radiological outcomes, and safetyand tolerability data.

Multiple sclerosis – escalation therapies and evidence-based medicine

doc. MUDr. Martin Vališ, Ph.D., MUDr. Zbyšek Pavelek

Neurol. praxi 2017; 18(Suppl F): 13-17 | DOI: 10.36290/neu.2017.124  

Multiple sclerosis is a chronic inflammatory demyelinating disease which affect central nervous system. Early treatment is thegoal due to high activity of imunopathological processes during the begining of this disease. If a treatment effect is insufficient ormissing then escalation therapy is indicated. Optimizing treatment in MS earlier may prevent accumulation of irreversible damage.

MRI efficacy of subcutaneous interferon ß-1a in treating multiple sclerosis

MUDr. Radek Ampapa

Neurol. praxi 2017; 18(Suppl F): 18-21  

Magnetic resonance imaging is an important tool in establishing the diagnosis of multiple sclerosis as well as in subsequentlymonitoring the success of immunomodulatory therapy in patients already diagnosed with the disease. Clinical signs are presentonly in a proportion of inflammatory lesions of the brain and spinal cord, and it is magnetic resonance imaging that helps to monitorthe clinically silent phase of the disease. Early treatment initiation is important for prognosis of the disease since irreversibleneurodegeneration occurs already at the onset of the disease. Subcutaneous interferon ß-1a was shown to have significant efficacyin reducing...

First line therapy and pregnancy in patients with multiple sclerosis – case reports

MUDr. Marko Petržalka

Neurol. praxi 2017; 18(Suppl F): 22-24 | DOI: 10.36290/neu.2017.125  

Multiple sclerosis is a chronic autoimmune neurodegenerative disease that affects predominantly young females in age spanbetween 20 and 40 years. Most of the patients would thus be in childbearing age. This article provides an insight into the therapyof patients planning pregnancy and on two cases-reports demonstrates the real clinical experience.

Differential diagnosis of common symptoms in ambulation of general neurologist

MUDr. Petra Praksová, Ph.D.

Neurol. praxi 2017; 18(Suppl F): 25-29 | DOI: 10.36290/neu.2017.126  

Diagnosis of multiple sclerosis (MS) requires exclusion of other neurological diseases that can clinically and radiologically mimicMS. Typical features of the first relapse of MS are unilateral optic neuritis, brainstem or cerebellar syndromes, partial spinal lesions.In the presence of atypical signs, red flags, more tests must be done for exclusion of other diseases. With the presentation of threeclinical cases of patients with suspicion of MS, this article shows some diagnoses that can mimic MS. Cases show importance ofcooperation with ophthalmologist. This article also shows importance of early diagnoses of MS for patient's prognoses and hisother...